Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01352273
Recruitment Status : Completed
First Posted : May 11, 2011
Last Update Posted : September 30, 2020
Information provided by (Responsible Party):
Array BioPharma ( Array Biopharma, now a wholly owned subsidiary of Pfizer )

Brief Summary:
This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and tolerability of concurrent administration of MEK162 and RAF265, followed by an expansion part to further assess the safety and preliminary anti-tumor efficacy of this oral combination within two separate patient populations: i) patients with advanced solid tumors harboring BRAFV600E mutations or ii) patients with advanced solid tumors harboring RAS mutations.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: MEK162 + RAF265 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Study Start Date : June 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Binimetinib

Arm Intervention/treatment
Experimental: MEK162 + RAF265 Drug: MEK162 + RAF265

Primary Outcome Measures :
  1. Incidence of Dose Limiting Toxicities [ Time Frame: during the first 28 days of treatment with RAF265 and MEK162 ]

Secondary Outcome Measures :
  1. Number of participants with adverse events and serious adverse events [ Time Frame: 18 months ]
  2. assess preliminary anti-tumor activity of the combination [ Time Frame: every 8 weeks of treatment ]
    CT scan will be performed

  3. Tumor skin and blood samples will be collected before and during treatment with RAF265 and MEK162 to assess the combination's effects on the RAF/MEK/MAPK pathway with the clinical outcomes [ Time Frame: 18 months ]
  4. Time versus plasma concentration profiles of RAF265 and MEK162 [ Time Frame: 10 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with histologically or cytologically confirmed and non-resectable advanced solid tumors for which no further effective standard therapy exists.

  • The patients' tumors must contain documented activating somatic BRAFV600E* , NRAS or KRAS mutations (except for pancreatic cancer)
  • All patients enrolled MUST provide fresh or archival tumor samples at baseline to enable central confirmation of BRAF or KRAS/NRAS mutations
  • Measurable, or non-measurable but evaluable disease as determined by RECIST
  • Adequate bone marrow function
  • Adequate hepatic and renal function
  • Adequate cardiovascular function
  • Negative serum β HCG test (female patients of childbearing potential only) within 72 hrs prior to first dose

Exclusion Criteria:

  • Patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
  • Current evidence of retinal disease; or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO (e.g., optic disc cupping, visual field defects, IOP > 21 mm Hg)
  • Impaired cardio-/vascular function or clinically significant cardiovascular diseases, including any of the following:

    • History/evidence of acute coronary syndromes (including MI, unstable angina, CABG, coronary angioplasty, or stenting) ≤ 6 months prior to starting study drugs
    • Thromboembolic event (DVT, CVA, PE) ≤ 6 months prior to starting study
    • Symptomatic CHF, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality
    • Uncontrolled arterial hypertension, defined as BP > 140/100 mmHg (average of 3 consecutive readings)
  • History of melena, hematemesis or hemoptysis within the last 3 months
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01352273

Layout table for location information
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
Tampa, Florida, United States, 33612
United States, Oregon
Oregon Health & Science University OHSU 3
Portland, Oregon, United States, 97239
United States, Utah
University of Utah / Huntsman Cancer Institute Huntman 2
Salt Lake City, Utah, United States, 84103
Canada, Alberta
Pfizer Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Quebec
Pfizer Investigative Site
Montreal, Quebec, Canada, H3T 1E3
Pfizer Investigative Site
Oslo, Norway, NO-0379
Pfizer Investigative Site
Madrid, Spain, 28050
Pfizer Investigative Site
Zürich, Switzerland, 8091
Sponsors and Collaborators
Array Biopharma, now a wholly owned subsidiary of Pfizer
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Layout table for additonal information
Responsible Party: Array Biopharma, now a wholly owned subsidiary of Pfizer Identifier: NCT01352273    
Other Study ID Numbers: CMEK162X2102
2010-023812-14 ( EudraCT Number )
First Posted: May 11, 2011    Key Record Dates
Last Update Posted: September 30, 2020
Last Verified: September 2020
Keywords provided by Array BioPharma ( Array Biopharma, now a wholly owned subsidiary of Pfizer ):
advanced Solid tumors
harboring RAS
harboring BRAFV600E
Additional relevant MeSH terms:
Layout table for MeSH terms